Loading...
Market
Rite Aid's market position by end of 2024
2
Resolution / Starting Odds
Top 3 • 33%
Top 4-6 • 33%
Below Top 6 • 33%
Market share data from industry analysis reports
Story
Rite Aid Wins $200 Million Dispute Over Elixir Sale After Judge's Monday Ruling
Jun 24, 2024, 06:00 PM
Rite Aid has successfully defeated MedImpact Healthcare Systems in a $200 million dispute over the sale of its pharmacy benefit manager, Elixir. A judge ruled on Monday that MedImpact is not entitled to recoup the $200 million in extra costs, as it assumed Elixir's debts when it acquired the company. This ruling absolves Rite Aid of any responsibility for the additional costs tied to the recent acquisition.
View original story
Similar markets
Increase by > 5% • 25%
Increase by ≤ 5% • 25%
Decrease by ≤ 5% • 25%
Decrease by > 5% • 25%
Net Profit • 25%
Net Loss < $100 Million • 25%
Net Loss $100-$500 Million • 25%
Net Loss > $500 Million • 25%
CEO Resigns • 25%
CFO Resigns • 25%
Both CEO and CFO Resign • 25%
No Changes • 25%
Below $5 billion • 25%
$5 billion to $10 billion • 25%
$10 billion to $15 billion • 25%
Above $15 billion • 25%
Pfizer • 33%
Johnson & Johnson • 33%
Eli Lilly • 33%
Amazon leads • 25%
Amazon in top 3 • 25%
Amazon in top 5 • 25%
Amazon outside top 5 • 25%
Sale completed • 25%
Sale abandoned • 25%
Sale to another party • 25%
No sale • 25%
Trust significantly improves • 25%
Trust slightly improves • 25%
Trust remains the same • 25%
Trust declines • 25%